QIAGEN(QGEN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - QIAGEN exceeded its fourth quarter 2025 Outlook with net sales of $540 million, growing 1% at constant exchange rates (CER) compared to flat sales development expected against Q4 2024 [5][12] - Adjusted diluted EPS for Q4 was $0.62 at CER, surpassing the Outlook of approximately $0.60 [5][12] - For the full year 2025, net sales reached $2.09 billion, up 5% at CER, at the upper end of the Outlook of 4%-5% growth [5][12] - Adjusted diluted EPS for the full year increased to $2.40 at CER, exceeding the initial Outlook by $0.12 [5][12] Business Line Data and Key Metrics Changes - Sample Technologies achieved 5% growth at CER in Q4 and 2% for the full year, driven by demand for automated consumables [6][13] - QuantiFERON sales grew 5% at CER in Q4 and 10% for the full year, supported by ongoing conversion in the latent TB testing market [7][14] - QIAstat-Dx grew 15% at CER in Q4 and 24% for the full year, aided by menu expansion and a growing install base [7][14] - QIAcuity saw double-digit growth in consumables, with over 3,200 instruments installed globally [7][14] - The bioinformatics business, QIAGEN Digital Insights, continued to grow, bolstered by demand from both research and clinical customers [8][24] Market Data and Key Metrics Changes - Sales in the Europe, Middle East, and Africa region increased by 5% at CER in Q4, with Belgium, the Netherlands, Spain, and the UK as top performers [16] - In the Americas, sales declined by 1% at CER, with the U.S. market remaining flat, partly due to the government shutdown [16] - Asia-Pacific-Japan region sales were flat, with a low-teens decline in China, which represents only about 4% of total sales [16][56] Company Strategy and Development Direction - QIAGEN aims for at least $2 billion in combined sales from its growth pillars by 2028, reflecting continued demand and long-term investment strategies [6][34] - The company is focused on disciplined execution, cost management, and investment in growth pillars, including the recent acquisition of Parse Biosciences to enhance Sample Technologies [9][19] - New product launches are expected to contribute significantly to growth, with QIAsymphony Connect and QIAmini targeting automation across various applications [20][68] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a cautious funding and capital spending environment but expressed confidence in achieving growth targets due to a strong pipeline of new product launches [32][66] - The company anticipates gradual improvement in the funding environment throughout 2026, with expectations for mid-single-digit growth in the total market [66] - QIAGEN's 2026 Outlook includes sales growth of at least 5% at CER and adjusted EPS of at least $2.50 at CER [26][31] Other Important Information - QIAGEN returned over $1.1 billion to shareholders since 2024 and plans to continue this trend alongside selective acquisitions [9][18] - The company is reviewing its adjusted operating income margin target of at least 31% for 2028, with expectations for continued margin improvement despite headwinds from tariffs and currency movements [17][31] Q&A Session Summary Question: Insights on new product launches and growth targets - Management highlighted that new product launches are expected to open new markets and contribute to growth, with confidence in achieving the $250 million target for digital PCR by 2028 despite previous delays [37][39] Question: Comments on potential acquisition rumors - Management stated that while the market is undergoing consolidation, QIAGEN remains focused on its growth plan and does not comment on rumors [45] Question: Update on CEO succession search - The search for a new CEO is ongoing, with both internal and external candidates being considered, and updates will be provided as progress is made [46] Question: Margin expansion and operating leverage - Management expects significant margin improvement in 2026, driven by gross margin improvements and operational efficiency programs, despite headwinds from acquisitions and tariffs [49][50] Question: Growth outlook in China - Management confirmed limited exposure to China, with expectations for low single-digit to negative growth due to market conditions and political factors [56][57] Question: QIAstat-Dx placements and respiratory season outlook - Management expressed confidence in achieving growth targets for QIAstat-Dx, with expectations for continued relevance in respiratory testing [71][72]